关于诺和笔®4的声明 

        诺和诺德（中国）制药有限公司（“公司”）一直致力于为患者提供高质量的药品和注射装置并确保患者的使用安全。近期，个别地方的患者向公司反映，在当地药店购买的诺和笔®4产品（胰岛素笔式注射器）使用数次后即不能正常使用。经公司调查，已经确认前述产品非公司生产，而是假冒的诺和笔®4。公司已向当地食品药品监督管理局报告了前述情况，当地食品药品监督管理局已经开始启动相关调查。

        由于使用假冒的诺和笔®4会导致胰岛素注射剂量严重不足，并导致血糖升高——最终影响对疾病的治疗。因此，公司特在此向广大患者提供鉴别真假诺和笔®4的信息，以使广大患者避免购买到假冒的诺和笔®4。同时，也提醒广大患者，在购买诺和笔®4时一定要到正规的医院和药店购买，不要从非正规的渠道购买，以免受骗上当。

                 正品的剂量显示窗  

                 假品的剂量显示窗

           正品旋转卡口底座    

            假品旋转卡口底座

                  正品外盒开封处

                  假品外盒开封处

        如果经过比较，您怀疑所购产品为假笔，我们建议您立即与当地食品药品监督管理局联系。

        为了保障患者的健康，公司会积极协助当地食品药品监督管理局对假品进行严厉打击。

Information about NovoPen^® 4

Novo Nordisk (China) Pharmaceuticals Co., Ltd. (the “Company”) is committed to provide high quality drugs and devices to patients and to safeguard patient safety. Recently the company was contacted by a few patients stating that the NovoPen^® 4 (an insulin delivery device) they had bought from local pharmacies could not be used as normal after several times of use. Following an investigation, Novo Nordisk has identified that these devices are not produced by the company but are counterfeit NovoPen^® 4. Novo Nordisk has reported these incidents of counterfeit NovoPen^® 4 to the local regulatory authorities, and an investigation has subsequently been carried out by the relevant related local authority.

The counterfeit NovoPen^®4 has a risk of delivering a too low amount of insulin which can cause an elevated blood glucose level  and affect the treatment of the disease. To avoid buying the counterfeit NovoPen^®4, the company hereby provides the below information in order to assist patients to distinguish genuine NovoPen^®4 from the counterfeit. Meanwhile, the company reminds the customers to buy NovoPen^®4 from the normal hospitals or pharmacies, instead of from an illegal source.

                     Genuine Pen

                    Counterfeit Pen

            Genuine Pen

            Counterfeit Pen

         Genuine Outer Carton

        Counterfeit Outer Carton

Should any products be suspected of being counterfeit after comparison with the above information, we highly recommend you immediately contact your local regulatory authorities.

Novo Nordisk is committed to combat counterfeit products and work closely together with authorities to safeguard the health of patients.


 

声   明

诺和诺德（中国）制药有限公司（“公司”）一直致力于为患者提供高质量的药品和注射装置并确保患者的用药安全。最近，个别地方的患者向公司反映其在当地药店购买的诺和龙^®产品与以往服用的诺和龙^®产品外观上有所不同。经公司调查，已经确认前述产品并非公司生产的诺和龙^®产品而是假冒的诺和龙^®产品，即假药。公司已向当地食品药品监督管理局报告了前述情况，当地食品药品监督管理局已经开始相关调查。

如果您怀疑您所购买的诺和龙^®产品的真伪，公司在此提供了相关信息以协助您对所购产品进行比较鉴别。如果经过比较，您怀疑所购产品为假药，我们建议您立即与当地食品药品监督管理局和公司联系。
这是诺和龙^®在中国上市10年以来，第一次发现假冒产品。为了保障患者的健康，公司会积极协助当地食品药品监督管理局对假药进行严厉打击。

STATEMENT

Novo Nordisk (China) Pharmaceuticals Co., Ltd. (the “Company”) is committed to providing high quality drugs and devices to patients and to safeguarding high standards of patient safety. Recently the company was contacted by a handful of patients stating that the NovoNorm^® tablets they had bought from local pharmacies appeared different to their usual NovoNorm^® tablets. Following an investigation, Novo Nordisk has identified that these few tablets are not drugs produced by the company but are counterfeit tablets. Novo Nordisk has reported these incidents of counterfeit NovoNorm^® tablets incidences to the Chinese regulatory authorities local FDA, and an investigation has subsequently been carried out by the relevant related local authorities.

Should patients be concerned their NovoNorm^® tablets are counterfeit, the company has provided the following information in order to assist in distinguishing genuine NovoNorm^® products from counterfeits. Should any products be suspected of being counterfeit after comparison with the information below, we highly recommend you immediately contact your local regulatory authorities and to the company.
This is the first time that Novo Nordisk has encountered counterfeit NovoNorm^® tablets since it was launched in China more than 10 years ago. The Company is highly committed to working with local regulatory authorities to fight counterfeit products, in order to safeguard the health of patients.
Guidelines for Distinguishing Counterfeit NovoNorm^®